Protalix Biotherapeutics (PLX) Stock Price, Quote & News

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 696 9345

Website: www.protalix.com

Address:

2 University Plaza, Suite 100, Hackensack, United States

calemay Aug. 24 at 3:53 PM

$PLX I really like the looks of the current daily trend. It’s held up nicely after a binary event. Will continue to rise on good news cycles. I set my next buy at 2.15 in case of a stop loss raid.

0 · Reply

crackpot Aug. 24 at 2:33 PM

$PLX I guess I'm looking for a statement like this from the company and/or analyst. Maybe it's been written many times and I haven't picked up on it? "ProCellEx is an FDA-validated alternative protein-expression platform whose unusual glycosylation and manufacturing characteristics may allow Protalix to develop differentiated biologics that are difficult, expensive or less therapeutically attractive using conventional expression systems." Add the value of this to the value of the success of two drugs approved and launched, the valuation should be substantially over $1 billion?

2 · Reply

PLATINUM_TRADES Aug. 24 at 12:25 PM

$PLX $2.55 Shouldn't be hard 🦻

0 · Reply

jcon777 Aug. 24 at 1:37 AM

$PLX I checked the transcript of the earnings call and did not see any mention of Secarna, but I also didn't expect much. If anyone knows more, I'd like to hear about it. Even speculative thoughts might be helpful to understand what the long term goals are with the Secarna relationship.

0 · Reply

tpbachli Aug. 22 at 12:28 PM

$PLX any one else co concerned about that after market dip ?

3 · Reply

USAEquityResearch Aug. 22 at 2:13 AM

$PLX 📊 USAEquityResearch ▲ 2.38 (+0.00%) Trend: Bullish 📈 RSI (14): 53.1 — neutral territory MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 2.62 | Support: 2.22 20-MA: 2.38 | 50-MA: 2.32 💼 Fundamentals Mkt Cap: $191.76M P/E (TTM): 10.3 | Fwd P/E: 3.8 FCF: $2.99M (0.04/sh) Total Debt: $9.21M D/E: 12.89 Educational content only. Not financial advice.

0 · Reply

jcon777 Aug. 21 at 9:12 PM

$PLX if this below statement proves to be true: Elfabrio Sales Guidance -- $33.0 million to $35.0 million for the full year 2026, excluding milestone payments And if PLX is getting approx 15% And if Chiesi gets the other 85% Then it appears we can do the math to see the total market share that Elfabrio would have for 2026

1 · Reply

jcon777 Aug. 21 at 4:15 AM

$PLX here's the transcript of the earnings call that does not require a login. https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/3931601/protalix-plx-q2-2026-earnings-call-transcript/

2 · Reply

Andrea31 Aug. 20 at 8:07 PM

$PLX Does anyone really think Chiesi won't acquire Protalix? Come on... They certainly wouldn't let an opportunity like that slip by...

3 · Reply

PLX_BULLS Aug. 20 at 4:42 AM

$PLX @crackpot for what it’s worth… Eyal often said 1 infusion expansion would take us to 35% of EMA ERT sales. Europe is 32% of Global ERT sales. Global Fabrys Disease Treatment is valued at approximately 2.5-3.1b; ERT grabs 75% of the aforementioned. Easy math let’s say global sales of 3b in 2027…. ERTs grab 2.25b and Europe ERTs are at 720m and Elfabrio/Chiesi grab 35% at 252m from just Europe… PLX is paid 76m at 35%. Let’s assume ROW and US equates to 75m and this takes us to 151m is revenue from Elfabrio and we can safely assume Elelyso will throw in another 25m to 176m. We could potentially add a 35-50m label expansion milestone for FDA expansion in 2027 too… taken us to >210m. Now I’ll take off 30m for being over zealous and that takes us to total revenues of 180m for 2027. Maybe 1.50 per share earnings.

3 · Reply

Protalix BioTherapeutics Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 12 days ago

Protalix BioTherapeutics Earnings release: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 12 days ago

Protalix BioTherapeutics Quarterly report: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 12 days ago

Protalix BioTherapeutics Slides: Corporate presentation

Aug 12, 2026, 6:50 AM EDT - 12 days ago

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Aug 5, 2026, 6:50 AM EDT - 19 days ago

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Protalix BioTherapeutics Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Protalix BioTherapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Protalix BioTherapeutics Slides: Corporate presentation

May 13, 2026, 6:50 AM EDT - 3 months ago

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 6, 2026, 6:50 AM EDT - 3 months ago

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Protalix BioTherapeutics Proxy statement: Proxy filing

Mar 18, 2026, 8:00 AM EDT - 5 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 5 months ago

Protalix BioTherapeutics Annual report: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 5 months ago

Protalix BioTherapeutics Earnings release: Q4 2025

Mar 18, 2026, 6:50 AM EDT - 5 months ago

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Mar 11, 2026, 6:50 AM EDT - 5 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

2026-03-09T10:16:17.000Z - 6 months ago

Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

Mar 9, 2026, 6:00 AM EDT - 6 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

2026-01-30T14:56:18.000Z - 7 months ago

Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing

Jan 30, 2026, 9:47 AM EST - 7 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Jan 30, 2026, 9:47 AM EST - 7 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Jan 5, 2026, 6:50 AM EST - 8 months ago

Protalix BioTherapeutics Letter to Stockholders

Dec 17, 2025, 6:50 AM EST - 8 months ago

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

2025-11-21T11:10:30.000Z - 9 months ago

Protalix price target lowered to $12 from $15 at H.C. Wainwright

Nov 13, 2025, 8:00 AM EST - 10 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Protalix BioTherapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

Protalix BioTherapeutics Earnings release: Q3 2025

Nov 13, 2025, 6:50 AM EST - 10 months ago

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Nov 6, 2025, 6:50 AM EST - 10 months ago

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

2025-10-17T11:11:05.000Z - 11 months ago

Protalix, Chiesi Global: CHMP issues negative opinion for Elfabrio

Oct 17, 2025, 6:58 AM EDT - 11 months ago

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Sep 16, 2025, 10:30 AM EDT - 1 year ago

Protalix BioTherapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 11, 2025, 10:55 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 2, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Registration statement: Registration Filing

Aug 14, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Aug 7, 2025, 12:53 PM EDT - 1 year ago

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

2025-07-21T10:55:33.000Z - 1 year ago

Protalix appoints Gilad Mamlok as CFO

Jul 21, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

2025-06-30T14:45:15.000Z - 1 year ago

Protalix added to Russell 3000, Russell 2000 Indexes

Jun 30, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

May 20, 2025, 4:30 PM EDT - 1 year ago

Protalix BioTherapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q1 2025

May 9, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 5, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

2025-04-28T21:05:49.000Z - 1 year ago

Protalix files $100M mixed securities shelf

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Protalix BioTherapeutics Registration statement: Registration Filing

Mar 24, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

2025-03-20T01:55:45.000Z - 1 year ago

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Annual report: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings release: Q4 2024

Mar 17, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Mar 10, 2025, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Feb 4, 2025, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

2025-02-03T11:15:19.000Z - 1 year ago

Protalix price target raised to $15 from $10 at H.C. Wainwright

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

2024-12-09T12:12:11.000Z - 1 year ago

Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission

Dec 9, 2024, 6:30 AM EST - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Quarterly report: Q3 2024

Nov 14, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 1 year ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 2 years ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Quarterly report: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q2 2024

Aug 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Transcript: Investor Day 2024

Jun 13, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 17, 2024, 8:00 AM EDT - 2 years ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Quarterly report: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q1 2024

May 10, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

May 3, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Protalix BioTherapeutics Proxy statement: Proxy Filing

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Annual report: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings release: Q4 2023

Mar 14, 2024, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Dec 26, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

calemay Aug. 24 at 3:53 PM

$PLX I really like the looks of the current daily trend. It’s held up nicely after a binary event. Will continue to rise on good news cycles. I set my next buy at 2.15 in case of a stop loss raid.

0 · Reply

crackpot Aug. 24 at 2:33 PM

2 · Reply

PLATINUM_TRADES Aug. 24 at 12:25 PM

$PLX $2.55 Shouldn't be hard 🦻

0 · Reply

jcon777 Aug. 24 at 1:37 AM

0 · Reply

tpbachli Aug. 22 at 12:28 PM

$PLX any one else co concerned about that after market dip ?

3 · Reply

USAEquityResearch Aug. 22 at 2:13 AM

0 · Reply

jcon777 Aug. 21 at 9:12 PM

1 · Reply

jcon777 Aug. 21 at 4:15 AM

2 · Reply

Andrea31 Aug. 20 at 8:07 PM

$PLX Does anyone really think Chiesi won't acquire Protalix? Come on... They certainly wouldn't let an opportunity like that slip by...

3 · Reply

PLX_BULLS Aug. 20 at 4:42 AM

3 · Reply

LQQKER_INSIDER Aug. 19 at 3:55 PM

$PLX LQQKER CONFESSIONS: I've always loved 💚 this little booger.

3 · Reply

Andrea31 Aug. 19 at 12:48 PM

$PLX Let's try today 2.50

0 · Reply

PLX_BULLS Aug. 18 at 12:36 PM

$PLX Reason for our drop …. MAK sold 3.5m shares or so.

4 · Reply

PickStocker Aug. 18 at 10:09 AM

$PLX Let's get this back above $2.50. PS: Is that Dror on the pic?

0 · Reply

brunoq14 Aug. 17 at 7:11 PM

$PLX We've been at $2.30 so many times. Why can't we hang out around $3.00 for a while?

0 · Reply

ElZocko2 Aug. 17 at 5:09 PM

$PLX AND: if Chiesi does not buy us with good gout data in 2028, they’ll never do.

1 · Reply

ElZocko2 Aug. 17 at 5:08 PM

$PLX just my guesstimation: working the 2-3$ range until mid of Q2 27. By end of 26 PRX-115 is fully enrolled. We will have better YoY data for revenue growth. Then 2nd half of Q2 27 the frontrunning data pump could slowly start to at least 4-5$. IF data is good, we could have a Chiesi partnership Q1 28 or a Chiesi BO in Q2/3 28. 4w FDA, unknown sales milestones etc could make us leave the boring area earlier. Anyway I believe we’ll leave it in Q2 27 latest. So conservative I expect to wait another 8-9 months before some real movements starts.

1 · Reply

BryGuy29 Aug. 17 at 5:06 PM

$PLX good day to sell more shares, I guess. Clearly , no interest in this stock. Trying to sell 2500 shares for fun, and took nearly 10 minutes with small 100-150 share lots being sold at a time. Pathetic.

1 · Reply

PLX_BULLS Aug. 17 at 4:35 PM

$PLX We’re in the Goldilocks Zone here…. Tutes/Indexes love profitable growing revenue streams that are undervalued. Back to Buy and Hold for a better day! We could potentially see 4.50$ before next earnings!

2 · Reply

Andrea31 Aug. 17 at 3:31 PM

$PLX It always drops fast, but climbs up slowly... the usual story.

1 · Reply

PickStocker Aug. 17 at 2:15 PM

$PLX Okay, so what's the next thing we're waiting for?

0 · Reply

Artfldgr Aug. 17 at 2:07 PM

$PLX i didn't want to say anything after it dropped. But in the back of my head i was thinking that it was that we were losing the weak hands who eaitrd and didn't have automated sell at up but instead reacted once they looked it it in the prior evening.

0 · Reply

Market Cap	191.76M
Revenue (ttm)	52.74M
Net Income (ttm)	-6.60M
EPS (ttm)	N/A
PE Ratio	10.35
Forward PE	10.82
Profit Margin	-12.51%
Debt to Equity Ratio	0.00

Volume	251,941
Avg Vol	687,232
Day's Range	N/A - N/A
Shares Out	80.57M
Stochastic %K	39%
Beta	0.02
Analysts	Strong Sell
Price Target	$11.00